Domestic pharmaceutical equipment industry inflection point, leading enterprises have growth potential

"
Pharmaceutical Network Market Analysis" In recent years, the domestic pharmaceutical equipment market competition is fierce, while the industry pattern has been continuously optimized, leading enterprises gradually increase dispossessionThe industry believes that, with the coming of the industry inflection point, the future pharmaceutical equipment industry leading enterprises will gradually enhance the profitability, optimistic about the development of leading enterprisesPharmaceutical Equipment (Source: Pharmaceutical Network)leading enterprises in the first quarter profitability performancecurrently, pharmaceutical equipment listed companies listed companies in 2019 performance report and the first quarter of 2020 report reports have been published, the profitability of leading enterprises performed wellFor example, Chutian Technology's 2019 annual results bulletin showed that the company achieved total operating income of RMB1,916 million in 2019, an increase of 17.45% over the same period last year, while net profit attributable to shareholders of listed companies was RMB48.5517 million, an increase of 17.52% over the same period last yearDongfulong's total operating income in 2019 was RMB2,275 million, up 18.70% YoY, while net profit attributable to shareholders of listed companies was RMB143 million, up 103.53% YoYNet profit attributable to shareholders of listed companies is expected to rise 190%-220% year-on-year to 46.1956 million yuan to 50.9744 million yuan in the first quarter of this yearIn response to the reasons for the increase in net profit, the company said that the beginning of the reporting period, continuing last year's development trend, pharmaceutical equipment sector and medical equipment sector revenue increased from a year earlierIn addition, during the reporting period, the company's expenses were well controlledCanaan Technology expects net profit attributable to shareholders of listed companies to increase by 60% to 90% in the first quarter of 2020 from a year earlier, with a profit of 5.5510 million yuan - 659.19 million yuanIt is reported that in the first quarter of this year, some downstream customers of pharmaceutical enterprises and logistics industry to resume production ahead of schedule, the company actively strengthen customer communication, serious lying work deployment, actively respond to and help customers to speed up the resumption of production, to ensure stable growth in business performanceThe 2019 results showed that Canaan Technology also achieved double growth in revenue and profit, up 23.91 percent and 54.80 percent, respectively, from a year earlieralso worth mentioning that since 2020, the orders of leading enterprises are also relatively adequate, such as Chutian first quarter of new orders increased by 20% compared to the same period last year, in the hands of orders sufficient; According to the National Development and Reform Commission Industry Department, the pharmaceutical manufacturing industry continued to perform well in April With the orderly progress of the resumption of production, the development of the pharmaceutical equipment industry will also speed up The industry expects that the profitability of leading companies in the pharmaceutical equipment industry will gradually increase in the future as the industry pattern continues to be optimized Domestic pharmaceutical equipment industry inflection point
in the long term, medicine as a new need, with the aging of the population, consumption level upgrade, new health insurance and other policies to promote the needs of China's pharmaceutical industry has great potential Data show that China's pharmaceutical market is expected to grow to $145 billion by 2022 and 230 percent by 2030 to 2017, making it the world's largest growth potential for the next decade in addition, the new version of the Drug Registration Management Measures to eliminate THE GMP certification, to strengthen the entire process of drug production and the entire life cycle of the dynamic supervision of drugs, the industry believes that the future demand for pharmaceutical equipment or will be released smoothly, the industry is expected to change from short-term explosive growth to long-term steady growth in this context, with resources, technology, capital and other strength of leading enterprises with obvious advantages, with greater growth potential, and therefore favored by the industry for example, the industry believes that the future of Dongfulong's revenue is expected to maintain steady growth, profitability gradually improved Companies to execute orders using the pre-receiving system, the average proportion of about 30% The company's pre-receiving spree, which reaches its highest level since Q1 went public in 2020, suggests that the company has sufficient hand orders, or that it is about to usher in a new round of earnings release periods in addition, Dongfulong's sterile injection equipment and overall solutions benefit from the continuous promotion of injection consistency evaluation, in recent years, the introduction of new biological, raw materials
and disinfection products with broad prospects, the amount of release in the immediate, optimistic about the company's long-term development potential The company is expected to achieve a net profit of 2.51, 323 and 405 million yuan from 2020 to 2022, respectively, up 72.5%, 28.4% and 25.3% yoy, with the first coverage giving a "buy" rating the author learned that some leading enterprises are also working to improve performance For example, Canaan Technology recently said on the interactive platform, the company is currently working through endogenous growth and extension of development to achieve industrial upgrading, improve the profitability of the company's various business sectors it is reported that in 2019, Canaan Technology in the pharmaceutical equipment business, powder process equipment series growth rate reached 66.84 percent With the expansion of production capacity of downstream customers' high-end generic pharmaceutical companies and the advancement of smart factory projects, the company expects the future of powder-based process equipment to continue to maintain steady growth.